Tau mutations serve as a novel risk factor for cancer by Giacomina, Rossi et al.
Tau mutations serve as a novel risk factor 
for cancer 
Article 
Accepted Version 
Giacomina, R., Redaelli, V., Contiero, P., Fabiano, S., 
Tagliabue, G., Perego, P., Benussi, L., Bruni, A., Filippini, G., 
Farinotti, M., Giaccone, G., Buitatiotis, S., Manzoni, C., 
Ferrari, R. and Tagliavini, F. (2018) Tau mutations serve as a 
novel risk factor for cancer. Cancer Research, 78 (13). pp. 
3731­3739. ISSN 0008­5472 doi: https://doi.org/10.1158/0008­
5472.CAN­17­3175 Available at 
http://centaur.reading.ac.uk/77726/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work.  See Guidance on citing .
To link to this article DOI: http://dx.doi.org/10.1158/0008­5472.CAN­17­3175 
Publisher: American Association for Cancer Research 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
1 
 
Tau mutations serve as a novel risk factor for cancer 
Giacomina Rossi
1#*
, Veronica Redaelli
1#
, Paolo Contiero
2
, Sabrina Fabiano
3
, Giovanna Tagliabue
3
, 
Paola Perego
4
, Luisa Benussi
5
, Amalia C. Bruni
6
, Graziella Filippini
7
, Mariangela Farinotti
8
, 
Giorgio Giaccone
1
, Simona Buiatiotis
9
, Claudia Manzoni
10,11
, Raffaele Ferrari
11
, and Fabrizio 
Tagliavini
7 
 
#
G. Rossi and V. Redaelli contributed equally and are co-first authors of this article. 
1
 Unit of Neurology V and Neuropathology,
 
Fondazione IRCCS Istituto Neurologico Carlo Besta, 
Milano, Italy 
2
 Environmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 
3 
Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 
4
 Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy 
5
 NeuroBioGen Lab—Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 
Brescia, Italy 
6
 Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy 
7
 Scientific Directorate, 
 
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy 
8 
Neuroepidemiology – Scientific Directorate,  Fondazione IRCCS Istituto Neurologico Carlo Besta, 
Milano, Italy 
9 
Department of Pathology, ASST Santi Paolo e Carlo, Milan, Italy 
10 
School of Pharmacy, University of Reading, Whiteknights, Reading, United Kingdom 
11 
Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom 
 
 
Running title: Tau mutations as a novel risk factor for cancer 
 
Research. 
on May 28, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2018; DOI: 10.1158/0008-5472.CAN-17-3175 
2 
 
Key words: neurodegeneration; cancer; tau; MAPT; mutation; risk factor; epidemiology; 
bioinformatics 
 
Conflict of interest: The authors declare no potential conflicts of interest 
 
 
 
*
Corresponding Author: Giacomina Rossi, PhD, Unit of Neurology V and Neuropathology, 
Fondazione IRCCS Istituto Neurologico Carlo Besta, via Amadeo 42, 20133 Milano, Italy. Tel.: 
+39 02 2394 4582; Fax: +39 02 2394 2101; E-mail: Giacomina.Rossi@istituto-besta.it 
Research. 
on May 28, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2018; DOI: 10.1158/0008-5472.CAN-17-3175 
3 
 
Abstract  
In addition to its well-recognized role in neurodegeneration, tau participates in maintenance of 
genome stability and chromosome integrity. In particular, peripheral cells from patients affected by 
frontotemporal lobar degeneration carrying a mutation in tau gene (genetic tauopathies), as well as 
cells from animal models, show chromosome numerical and structural aberrations, chromatin 
anomalies, and a propensity toward abnormal recombination. As genome instability is tightly linked 
to cancer development, we hypothesized that mutated tau may be a susceptibility factor for cancer. 
Here we conducted a retrospective cohort study comparing cancer incidence in families affected by 
genetic tauopathies to control families. Additionally, we carried out a bioinformatics analysis to 
highlight pathways associated with the tau protein interactome. We report that the risk of 
developing cancer is significantly higher in families affected by genetic tauopathies, and a high 
proportion of tau protein interactors are involved in cellular processes particularly relevant to 
cancer. These findings disclose a novel role of tau as a risk factor for cancer, providing new insights 
in the various pathological roles of mutated tau. 
Significance. This study reveals a novel role for tau as a risk factor for cancer providing new 
insights beyond its role in neurodegeneration 
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Introduction 
Cancer arises from sequential accumulation of genomic alterations, including mutations in 
oncogenes and tumour suppressor genes (1). Over the years different models of oncogenesis have 
been proposed (2), in which an initiating event often caused by a mutation leads to genomic 
instability, comprising: (i) subtle sequence instabilities (base pair substitutions, deletions or 
insertions of few nucleotides), favoured by mutations in genes involved in the DNA nucleotide-
excision and mismatch repair systems; (ii) chromosome instability (CIN), in particular aneuploidy, 
defined as loss or gain of whole chromosomes or large fragments thereof, that occurs following  
mutations in genes involved in cellular processes affecting correct chromosome segregation, such as 
chromosome condensation, chromatid cohesion, kinetocore assembly, centrosome 
replication/microtubule dynamics, DNA repair and cell cycle checkpoints (3-5). Overall, these types 
of genomic instability can cause changes in sequence, structure or allelic number of tumour genes, 
leading cancer cells to acquire functional capabilities that allow them to survive, proliferate and 
metastasize. 
Microtubule-associated proteins (MAPs) are defined as proteins promoting in vivo tubulin self-
association into microtubules (MT). Other proteins interacting with MT have different functions 
such as MT destabilization, linking of various structures and motor properties. Most of these MT-
related proteins play a role in mitotic spindle formation, ensuring correct chromosome segregation 
(6,7). Among MAPs, tau is the most relevant to the nervous system, being abundantly expressed in 
neurons. Deposition of insoluble filamentous forms of tau gives rise to tauopathy, a neuronal 
pathology that leads to dementia and atypical parkinsonian syndromes (8). Tau binds to interphasic 
cytoskeleton MT as well as to mitotic spindle MT (9-11). A mutated tau usually exhibits a reduced 
ability to bind to MT and to promote their assembly (12), altering MT dynamics (13,14). This can 
lead to an unstable mitotic spindle, from which chromosome mis-segregation can arise, causing 
aneuploidy.  
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In this regard, we demonstrated the consistent presence of aneuploidy in peripheral cells of patients 
affected by frontotemporal lobar degeneration (FTLD) due to autosomal dominant mutations in 
microtubule-associated protein tau (MAPT) gene, suggesting a role of tau in chromosome and 
genome stability (11,15). In addition, it has been reported that tau knock-out mice show 
chromosome mis-segregation and aneuploidy (16). Based on these studies and as previously 
suggested (3), we hypothesized that mutated tau can cause CIN resulting in aneuploidy. Aneuploidy 
is frequently observed in cancer cells, where it can lead to loss of heterozygosity of tumour 
suppressor genes or amplification of oncogenes, thereby contributing to tumorigenesis.  
Moreover, a different type of CIN was observed in cells of our patients carrying mutated tau, i.e. 
structural chromosome aberrations (11,15), that may be ascribed to defects in DNA single- or 
double-strand break repair or in DNA-damage checkpoint (3), to telomeric DNA loss or telomerase 
defects (17), or to alterations in proteins contributing to chromatin stability, predisposing to a higher 
rate of DNA damage. Whereas there is no evidence of the involvement of tau in DNA repair 
systems (15) or in telomere preservation, a chaperone role of tau in protecting DNA from free 
radicals and heat stress damage has recently emerged (18,19), as well as a structural role of tau in 
chromatin stabilization (15). 
Based on these findings, we hypothesized that CIN associated with tau mutations can lead to 
cancer. Thus, we propose a dual pathogenic role of tau mutations, in cancer and neurodegeneration. 
Cancer and neurodegeneration have been proven to share alteration of some biological pathways 
such as cell cycle, apoptosis, ubiquitin-proteasome system (20,21). These pathways are usually 
differentially regulated in cancer and neurodegeneration due to the different nature of the impacted 
cells, that is, proliferating or post-mitotic, respectively. Cell cycle is dysregulated in cancer, where 
control over cell proliferation is inhibited, and in some forms of neurodegeneration, where 
abnormal re-entry of post-mitotic cells into the proliferating phase eventually leads to neuronal 
death via apoptosis (21,22). The tumor suppressor protein p53 plays a pro-apoptotic role and, while 
protecting the body from cancer, it promotes the aging phenotype through cellular loss. Its 
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deficiency by mutation can lead to higher cancer risk on one hand, and lower degree of 
neurodegeneration on the other (21). The ubiquitin-proteasome system, while impaired in 
neurodegenerative diseases and leading to misfolded protein accumulation, is upregulated in several 
types of cancer (21). A recent study showed that transcripts up-regulated in cancer are down-
regulated in central nervous system diseases and vice versa. In line with this finding, a reduced risk 
for developing some types of cancer has been observed in patients affected by Parkinson’s disease 
(PD) and Alzheimer’s disease (AD) (23).  
Metabolic dysregulation, oxidative stress, DNA damage and inflammation have been shown to be 
initiating events for both cancer and neurodegeneration (21). In addition, a number of genes (i.e. 
ATM, PARK2 and LRRK2) are known to confer risk for both cancer and neurodegeneration. ATM 
plays a central role in cell division and DNA repair: homozygous mutations cause ataxia-
teleangectasia, with degeneration of some cerebellar neurons, and predispose to high frequency to 
cancer, especially to lymphomas (24). PARK2, the most commonly mutated gene in autosomal 
recessive PD (25), is a well-known tumor-suppressor gene, whose loss of function mutations are 
associated with cancer (26). Similarly LRRK2, the most frequently mutated gene in late-onset PD 
has been linked to increased risk of some types of cancers (27).  
Similarly to what happens for ATM, PARK2 and LRRK2 mutations, we here suggest that tau 
mutations may lead to both neurodegeneration and cancer. In fact, if tau is altered by a mutation, its 
role as MT-binding protein can lead to cytoskeleton disruption and tau deposits in 
neurodegeneration, and chromosome missegregation and aneuploidy in cancer; furthermore, its role 
as DNA-chaperone can lead to DNA damage and apoptosis in neurodegeneration and structural 
chromosome aberrations in cancer. 
To verify the hypothesis that CIN associated with tau mutations can lead to cancer, we conducted a 
retrospective cohort study comparing cancer incidence in families affected by FTLD carrying tau 
mutations and reference families with superimposable pedigrees, and carried out a bioinformatics 
analysis of pathways associated with the tau protein interactome. We found that (i) members of 
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FTLD families have a significantly higher risk of developing cancer than members of control 
families, and (ii) 1/3
rd
 of the tau interactors are involved in DNA damage recognition and repair, 
cell cycle checkpoints and phase transition, chromatin and telomere maintenance processes, and 
response to radiation stressors, supporting a role for tau in DNA protection/repair systems. 
 
Materials and Methods 
All the subjects participating in the study gave their written informed consent for using their clinical 
and genetic data for research purposes. All the procedures involving human subjects were done in 
accordance with the Helsinki Declaration of 1975. As this is a retrospective study, approval by an 
Ethics Committee was not required. 
 
Pedigrees 
We considered FTLD kindreds with a family history of disease and a mutation in the MAPT gene 
(detected by sequencing of exons 1, 9-13). We analysed 15 families bearing 7 different tau 
mutations. We designed this study as a retrospective cohort study, where tau-mutated families 
represented the “exposed cohort”. For each tau-mutated family we collected data from 3 reference 
families with superimposable pedigrees, with a member born in the same year of the proband, of the 
same gender and native Italian region. To retrieve comparable informative data for all the tau-
mutated families, the pedigrees were accurately investigated for the presence of cancer in: 1) the 
proband, 2) his/her siblings, 3) the parent whose family is affected by FTLD, 4) his/her siblings, 5) 
the grandparent affected by FTLD. 
Clinical data were obtained from interviews with relatives and family doctors or directly from 
available clinical charts. For the reference families, the same methods were applied, except both 
paternal and maternal lines were investigated. Follow up was assessed by interviews for both tau-
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mutated families and reference families. Where it was not possible to obtain an answer we used 
social security list to update vital status (2%). 
 
Statistical methods 
We compared cancer incidence for the tau-mutated families versus the reference families. In the 
analysis of tau-mutated families, we did not include the spouses and all the grandparents for which 
the information about presence of FTLD was not available (subjects in gray in Figure 1). We did 
not include 2 subjects affected by cancer whose genotype was wild-type (see legend of Figure 1). 
The statistical analyses are based on the Cox proportional hazard model which specifies the hazard 
as λ (t)=λ0(t)exp (βX), where λ(t) is the hazard function for the event in question (cancer 
incidence). X is a vector of covariates, and β is a vector of coefficients to be estimated. The hazards 
for two participants with fixed covariate vectors Xi and Xj are λi (t)=λ0(t)exp(βXi) and λj 
(t)=λ0(t)exp (βXj), respectively. The hazard ratio (HR) is λi(t)/λj(t)=exp (β(Xi−Xj)). To test the null 
hypothesis H0 that β=0, we used the likelihood ratio test. Since the Cox model assumes 
proportional hazards, this was tested by analysis of scaled Schoenfeld residuals, with associated p-
values. When the hazard was suspected to be non-proportional over time, we performed additional 
analyses, substituting the conventional Cox β coefficient (for a given variable) with a time-
dependent function β(t) obtained by adding the smoothed scaled Schoenfeld residuals to the 
conventional β coefficient.  
Factors known or thought to influence cancer incidence in the tau-mutated families were initially 
analysed by univariate Cox proportional hazard modelling to verify the effect on incidence in our 
retrospective cohort. Factors analysed were gender, year of birth and region of origin. We next ran 
multivariate Cox proportional hazard models to estimate HRs with 95% CIs of cancer events. The 
multivariate model was stratified (separate baseline hazard functions for each variable category 
within the model) by the same factors above to control for the possible confounding effects of these 
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variables on incidence. Time to event or end of follow-up was calculated from date of birth to date 
of cancer diagnosis or death or end of follow-up. 
Data analysis was carried out using R-language.  
 
Bioinformatics analysis of tau protein interactome 
We built the tau weighted protein-protein interactome by extracting all the currently known tau’s 
protein-protein interactors (PPIs), obtained from peer reviewed literature filtered and scored by our 
in house pipeline in a supervised manner (28). Briefly, we downloaded PPIs (in June-2017) from 
the following databases within the IMEX consortium: APID Interactomes, BioGrid, bhf-ucl, 
InnateDB, InnateDB-All, IntAct, mentha, MINT, InnateDB-IMEx, UniProt, and MBInfo by means 
of the “PSICQUIC” R package (version 1.15.0 by Paul Shannon, 
http://code.google.com/p/psicquic/). We converted Protein IDs to Swiss-Prot and Entrez gene ID; 
we removed TrEMBL, non-protein interactors (e.g. chemicals), obsolete Entrez and Entrez 
matching to multiple Swiss-Prot identifiers. All PPIs underwent quality control (QC) and filtering 
leading to the removal of: i) all the non-human taxid annotations; ii) all the annotations with 
multiple or none PubMed identifiers or no description of Interaction Detection Method. We then 
scored the interactions taking into consideration the following parameters: i) the number of different 
publications reporting the interaction; ii) the number of different methods reporting the interaction. 
We discarded all the interactors with a final score ≤ 2 because (still) not replicated. We performed 
Gene Ontology (GO) biological processes (BPs) enrichment analyses in g:Profiler (g:GOSt, 
http://biit.cs.ut.ee/gprofiler/; (29)) for the complete tau’s interactome. Fisher's one-tailed test was 
used as statistical method for enrichment; SCS-threshold was applied as multiple testing correction; 
statistical domain size was only annotated genes; no hierarchical filtering was included. We 
grouped enriched GO-BP terms into custom-made “semantic classes”. Data was handled, filtered 
and scored through in-house R scripts (https://www.r-project.org/) as described before (28). The 
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final network was visualized through the freely available Cytoscape 2.8.2 (30) software and 
analyzed through the network analysis plug-in.  
 
 
Results 
Epidemiology 
The study population comprised 15 families bearing 7 different tau mutations (Fig. 1), whose 
FTLD-related pathogenic mechanisms are reported in Table 1. For four of these mutations, we 
demonstrated chromosome or genomic instability (11;15; Supplementary Table S1). As controls, 
for each tau-mutated family we selected three reference families with a member born in the same 
year of the proband, being of the same gender and native of the same Italian region. Demographics 
of both tau-mutated and reference families is shown in Table 2, while further details for reference 
families and regions of origin are reported in Supplementary Table S2. 
All families were accurately investigated for the presence of cancer. Within the tau-mutated 
families, 24 subjects (15%) had cancer, while within the reference families 68 subjects (9%) had 
cancer. The mean age at diagnosis of subjects with cancer was 58 years, while the average age of 
dementia onset was 50 years. The types of cancer detected in tau-mutated and reference families are 
reported in Supplementary Table S3. A great variability was observed in both cohorts, showing no 
recurrence of a particular type of cancer even in tau-mutated families. 
Factors known or thought to influence cancer incidence such as gender, year of birth and region of 
origin were initially analysed by univariate Cox proportional hazard model (Table 3A). The study 
showed that the tau-mutated families had significantly greater risk of cancer than the reference 
families (HR = 3.11), and, when the gender variable was assessed, the risk in females appeared to 
be greater than in males, though not significant (HR = 1.16). We then performed multivariate Cox 
proportional hazard model to estimate HRs with 95% CIs of cancer events. The model was stratified 
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by gender, year of birth and region of origin to control for potential confounding effects on 
incidence of cancer. The likelihood ratio test resulted in p = 0.0005, supporting robust association 
between the presence of a tau mutation and the development of cancer with HR = 3.72 (CI 95% 
2.07 – 6.67), thus indicating a nearly 4-fold risk of developing cancer in tau-mutated families (Table 
3B). 
 
Bioinformatics analysis of tau protein interactome 
We generated a two layers interactome for tau (Fig. 2). The first layer interactors (65 nodes) are 
directly connected to tau, whilst the second layer interactors (3132 nodes) represent the interactors 
of each first layer node thus diluting the seed centrality bias as previously reported (28). The global 
tau’s interactome comprised a total of 3197 nodes and 5711 edges, with characteristic path length of 
3.407 and average number of neighbors of 3.3 (Fig. 2A). To gather insight into the biological 
functions associated with tau’s entire interactome we performed functional annotation analysis 
evaluating Gene Ontology-Biological Processes (GO-BPs) enrichment (Supplementary Table S4). 
Some of the biological functions enriched within tau’s interactome were expected (e.g. cytoskeleton 
dynamics and transport). Nevertheless, nearly 1/3
rd
 of the proteins contributing to the entire tau’s 
interactome (989/3197) was directly involved in the enrichment of GO-BPs terms globally pointing 
to DNA METABOLISM and, particularly, to DNA damage, stress response to radiation, DNA 
damage checkpoint and repair, and cell death after DNA damage; additionally, we found terms 
related to CELL CYCLE, particularly, indicating cell cycle checkpoints and chromosome 
segregation, and CHROMATIN, the latter pointing to processes such as histone and telomere 
maintenance (Table 4; Fig. 2B). Importantly, to assess the specificity of the enrichment reported 
above, we generated 25 random protein sets (by extracting a series of numbers using random 
permutation without replacement in R) with similar size to the tau’s interactome and processed 
them through functional enrichment. Out of the 25 protein sets, only 8 (32%) led to a significant 
functional enrichment. Only 1/8 random protein set revealed 0.8% enriched terms that were similar 
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to those reported for tau. Considering the former (0.8%) against the latter (30.9%) (Supplementary 
Table S5), it follows that the specificity of tau’s interactome is strong and unbiased. 
 
 
Discussion 
It is well established that tau, as a MT-binding protein, is a major player in neurodegenerative 
diseases also known as tauopathies, such as FTLD and AD. Cytoplasmic abnormal tau deposits 
represent a burden to neurons and glial cells, whilst toxic soluble tau oligomers are now being 
envisaged as responsible for the neuronal dysfunction and death (8,31).  
However, other lines of evidence suggest that tau may be also involved in other functions. Nuclear 
and nucleolar localizations of tau were first described several years ago (32-34) and, more recently, 
a role of tau in ribosome biogenesis was suggested (35). We confirmed the nuclear and peri-
chromosomal localization of tau and, in addition, discovered that FTLD patients bearing the P301L 
tau mutation had several numerical and structural chromosome aberrations and chromatin defects in 
their peripheral blood lymphocytes and fibroblasts (11). 
A number of observations argued for a link between mutated tau and chromosome aberrations: 1) 
tau’s physical association with mitotic spindle, thus possibly regulating correct chromosome 
segregation; 2) tau’s nuclear localization and its physical interaction with the chromatin (36); 3) 
tau’s ability to protect DNA in vitro (37). Additionally, a link between tau and genome integrity 
was evidenced when tau was shown to translocate from the cytoplasm to the nucleus during cellular 
stress and to protect DNA from stress-induced DNA breaks (19). Furthermore, in an in vivo mouse 
model of heat stress, tau was shown to protect genomic DNA and also RNA from oxidative damage 
(38), whilst in a tau knock-out mouse model, the absence of tau caused disruption of the neuronal 
peri-centromeric heterochromatin, which showed an abnormal accumulation of DNA breaks (39). 
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Our group examined peripheral cells of FTLD patients carrying different tau mutations and 
demonstrated chromosome aberrations, as well as a tendency to abnormal recombination events, 
indicating genome instability (15). All the more, in two mouse models of genetic tauopathy, we 
detected a higher level of aneuploidy than in control mice (40). More recently, in a Drosophila 
melanogaster model of tauopathy, mitotic spindle anomalies and aneuploidy were observed after 
overexpressing wt tau (41). 
Aneuploidy is a condition often associated with cancer. An aneuploid karyotype can or cannot 
promote cancer depending on its inherent imbalance of oncogenes or tumor suppressor genes, and 
other genes controlling cell viability and fitness. It has been proposed that in the harsh cell 
environment experimented by cancer cells, aneuploidy may conceivably confer an advantage and 
promote cancer cells’ survival and proliferation (42). Similar considerations apply to structural 
chromosome aberrations. 
We therefore hypothesized that tau mutations might predispose to cancer. We had access to a 
retrospective cohort of families affected by genetic tauopathies (tau-mutated families) and 
investigated the potential link between tau mutations and cancer. We surveyed the presence of any 
type of cancer in subjects within tau-mutated families. In parallel, we collected reference families to 
compare cancer incidence. For the period of time when most of the tau-mutated families’ subjects 
had lived there was not any national or regional cancer registry available, therefore, in the setting of 
retrospective studies, the most appropriate analysis model we could choose was the cohort model. 
Multivariate analysis correcting for the possible confounding factors showed that the presence of 
tau mutation raises the risk of developing cancer by 3.72 times, assigning to tau mutation a 
prominent role as a risk factor for cancer. If we accept the definition of moderate risk (in terms of 
disease incidence) as a risk two to four times as high as in the general population, we can affirm that 
MAPT mutations, as in the case of other genes such as ATM or CHEK2 (43), represent a moderate 
risk factor for cancer.  
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This finding was further supported by our computational analysis where we applied a systems 
biology approach focused on the tau protein interactome on the basis of the guilt by association 
principle (i.e. the unknown function of protein A can be inferred via the known function of protein 
B if A and B interact) (44). Functional annotation analysis of the in silico model of tau’s 
interactome showed that over 1/3
rd
 of tau interactors was directly involved in functions such as 
DNA damage, response to radiation stressors, DNA damage checkpoint, repair and cell death, cell 
cycle checkpoints and chromatin maintenance, processes that are arguably associated with cancer; 
this is cross-supportive with previous computational work when considering tau’s co-expression or 
PPI-networks analyses in FTLD (28,45). 
Bridging the in silico and functional data, and considering in particular the cell cycle checkpoints, it 
has in fact been shown, in a Drosophila model of tauopathy, that human mutations cause 
neurodegeneration by abnormally activating the cell cycle in post-mitotic neurons (46), or can 
induce heterochromatin relaxation, DNA damage and widely altered gene expression with cell cycle 
activation (47,48). While abnormal neuronal cell-cycle reentry is now accepted as a phenomenon 
associated with neurodegeneration (22,49), the ability of mutated tau to activate the cell cycle in 
different tissues should be taken into account as a possible risk factor for abnormal cell 
proliferation, linking cancer and neurodegeneration. On the other hand, the DNA damage 
checkpoint mediated by ATM and p53 appears to be protective in mouse and Drosophila models of 
tauopathy, again linking neurodegeneration and cancer (50). 
Figure 3 synthetically illustrates the possible mechanisms through which mutated tau can increase 
the risk of developing cancer. In particular, chromosome missegregation, leading to aneuploidy 
(Fig. 3A), chromatin damage, causing structural chromosome aberrations (Fig. 3B), and abnormal 
cell cycle activation (Fig. 3C) are depicted. 
The types of tumors that we detected in tau-mutated families were variable, ranging from 
haematological (e.g. leukemias) to solid, from common (lung, breast, colorectal cancer) to rare, 
from benign (e.g. leiomyoma) to malignant, from strictly epithelial to teratomas (e.g., ovarian 
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teratoma). This spectrum suggests that tau mutations may represent a risk factor predisposing to 
genomic instability with no tissue specificity, as previously suggested by the presence of different 
and not recurrent types of chromatin and chromosome aberrations in FTLD patients (15). 
By interrogating publicly available RNA/protein expression databases, we verified that tau was 
detected in almost all evaluated tissues (in both normal as well as cancerous tissues/cell lines) 
(Supplementary Table S6). It may be also worth considering that, due to the metastatic nature of 
many cancers, the tissue where a cancer is detected – as indicated in Supplementary Table S2 –may 
not be the primary tumor site and may thus be independent of tau’s site-specific expression. 
As shown in Figure 1, as well as in Supplementary Table S2, there are some families without 
cancer-affected subjects. As tau mutations do not represent a causative but a risk factor for cancer, it 
may be that not every subject carrying the mutation will develop cancer, and by pure chance it is 
possible that in a tau-mutated family there should not be cancer-affected subjects. This is the case of 
Fam11, Fam15 and Fam8, whereas other families carrying the same mutation show cancer-affected 
subjects; this may also be the case of the V337M mutation. However we do not exclude that some 
mutations may be less cancer-predisposing than others, depending on their position in the protein or 
their amino-acid change, which may affect to a minor degree the microtubule-binding capacity or 
the DNA-chaperone ability, involved in the cancer development. This may for example be the case 
of the V337M mutation. 
In summary, we here show that tau’s functions go beyond assuring MT stability, as we demonstrate 
its nuclear involvement and association with genome stability and increased risk for cancer. This is 
a novel concept for tau’s biology and, in line with other reports tying cancer and neurodegeneration 
(20,21), it might prove critical for a better understanding of both cancer and neurodegeneration (i.e. 
tauopathies) etiologies. As such it is warranted to further explore tau-associated molecular 
mechanisms as a mean for untangling manifold disorders. 
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Table 1. Pathogenetic mechanisms of tau mutations 
 
n.a. = not available. 
a
Reference 12; 
b
Reference 15; 
c
Reference 11; 
d
this study, Supplementary Table 
S1. 
 
Number of 
families in this 
study 
Tau mutation Reported pathogenetic mechanisms
a
 Chromosome 
aberrations  
1 N279K tau isoform imbalance; increase of tau self-
aggregation. 
n.a. 
1 delN296 reduction of MT polymerization; slower 
kinesin translocation along MT 
yes
b
  
8 P301L reduction of MT polymerization; increase of 
tau self-aggregation; slower kinesin 
translocation along MT 
yes
b,c
 
2 IVS10+16C>T tau isoform imbalance yes
b
 
1 V337M reduction of MT polymerization; increase of 
tau self-aggregation  
n.a. 
1 V363A reduction of MT polymerization; oligomer 
production 
yes
d
 
1 T427M n.a. n.a. 
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Table 2. Cohort demographic 
 
N° of subjects of 
the whole cohort  
N° of subjects of  
tau-mutated families 
N° of subjects of 
reference families 
Total subjects 879 162 717 
Subjects with dementia   68   
Subjects with cancer   16 68 
Subjects with dementia 
and cancer  8  
Gender       
M 473 94 379 
F 406 68 338 
Period       
1877-1916 107 5 102 
1917-1936 210 24 186 
1937-1956 232 46 186 
1957-1996 219 50 169 
1997-2013 111 37 74 
 
 
Table 3A. Univariate analysis HRs and 95% CI for cancer risk 
HR (95% CI) 
univariate 
Tau exposure  3.11 (1.93 – 5.31) 
Gender 1.16 (0.76 - 1.74) 
 
 
Table 3B. Multivariate analysis HRs and 95% CI for cancer risk 
   
HR (95% CI)  
  multivariate 
  3.72 (2.07 – 6.67)* 
    
  *Multivariate stratified by gender, year of birth and region of origin 
 
Research. 
on May 28, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2018; DOI: 10.1158/0008-5472.CAN-17-3175 
25 
 
Table 4. Summary of Gene Ontology - Biological Processes (GO-BPs) terms enriched within the 
tau interactome and generally relevant to cancer. 
For each semantic class the top GO terms are reported (based on t-depth). 
p-value term ID t name t depth Semantic class
5.88E-09 GO:0071156 regulation of cell cycle arrest 6 cell cycle
3.14E-08 GO:0071158 positive regulation of cell cycle arrest 6 cell cycle
1.49E-07 GO:0044819  mitotic G1/S transition checkpoint 9 cell cycle - checkpoint
5.53E-07 GO:0072413  signal transduction involved in mitotic cell cycle checkpoint 7 cell cycle - checkpoint
9.28E-08 GO:0072395 signal transduction involved in cell cycle checkpoint 6 cell cycle - checkpoint
7.13E-12 GO:0007093 mitotic cell cycle checkpoint 6 cell cycle - checkpoint
1.85E-15 GO:0000075  cell cycle checkpoint 5 cell cycle - checkpoint
5.58E-06 GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity 6 cell cycle - enzyme
1.37E-13 GO:2000045 regulation of G1/S transition of mitotic cell cycle 8 cell cycle - phase transition
3.28E-08 GO:2000134 negative regulation of G1/S transition of mitotic cell cycle 8 cell cycle - phase transition
7.20E-06 GO:0010389 regulation of G2/M transition of mitotic cell cycle 8 cell cycle - phase transition
2.37E-03 GO:0010972 negative regulation of G2/M transition of mitotic cell cycle 8 cell cycle - phase transition
4.68E-02 GO:0010824  regulation of centrosome duplication 7 cell cycle - segregation/cytokinesis
6.12E-12 GO:0000280 nuclear division 6 cell cycle - segregation/cytokinesis
3.78E-10 GO:0007088 regulation of mitotic nuclear division 6 cell cycle - segregation/cytokinesis
2.11E-09 GO:0051783 regulation of nuclear division 6 cell cycle - segregation/cytokinesis
7.23E-03 GO:0033045 regulation of sister chromatid segregation 6 cell cycle - segregation/cytokinesis
3.37E-02 GO:0051988 regulation of attachment of spindle microtubules to kinetochore 6 cell cycle - segregation/cytokinesis
3.58E-02 GO:0032465 regulation of cytokinesis 6 cell cycle - segregation/cytokinesis
6.04E-04 GO:0046605 regulation of centrosome cycle 6 cell cycle-cytoskeleton
6.51E-03 GO:0090307 mitotic spindle assembly 6 cell cycle-cytoskeleton
3.93E-10 GO:0032206  positive regulation of telomere maintenance 7 chomatin - telomere
1.54E-08 GO:0032212  positive regulation of telomere maintenance via telomerase 7 chomatin - telomere
6.17E-03 GO:0032205  negative regulation of telomere maintenance 7 chomatin - telomere
8.52E-14 GO:0032200 telomere organization 6 chomatin - telomere
1.04E-03 GO:0090671 telomerase RNA localization to Cajal body 6 chomatin - telomere
7.16E-03 GO:1904814 regulation of protein localization to chromosome, telomeric region 6 chomatin - telomere
1.04E-03 GO:0090672  telomerase RNA localization 5 chomatin - telomere
3.02E-09 GO:1905269  positive regulation of chromatin organization 7 chromatin - organisation 
1.99E-07 GO:0031056  regulation of histone modification 7 histone
2.79E-07 GO:0031058  positive regulation of histone modification 7 histone
4.40E-03 GO:0070932 histone H3 deacetylation 8 histone - acetylation
3.25E-02 GO:0035065 regulation of histone acetylation 8 histone - acetylation
1.12E-07 GO:0016572  histone phosphorylation 7 histone - phosphorylation
5.64E-16 GO:0042770 signal transduction in response to DNA damage 6 DNA metabolism - damage
1.50E-03 GO:0006975 DNA damage induced protein phosphorylation 6 DNA metabolism - damage
6.84E-06 GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator 8 DNA metabolism - damage - cell death
2.82E-04 GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage 8 DNA metabolism - damage - cell death
2.48E-14 GO:0008630  intrinsic apoptotic signaling pathway in response to DNA damage 7 DNA metabolism - damage - cell death
3.27E-03 GO:1902230  negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage 7 DNA metabolism - damage - cell death
1.49E-07 GO:0031571 mitotic G1 DNA damage checkpoint 10 DNA metabolism - damage - checkpoint
5.48E-06 GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest 10 DNA metabolism - damage - checkpoint
5.53E-07 GO:1902402  signal transduction involved in mitotic DNA damage checkpoint 9 DNA metabolism - damage - checkpoint
1.75E-06 GO:0072431  signal transduction involved in mitotic G1 DNA damage checkpoint 9 DNA metabolism - damage - checkpoint
4.56E-05 GO:0006289  nucleotide-excision repair 7 DNA metabolism - repair
2.38E-02 GO:0006302  double-strand break repair 7 DNA metabolism - repair
1.43E-06 GO:0034644  cellular response to UV 7 response to stimulus - stress - radiation
2.51E-03 GO:0071480  cellular response to gamma radiation 7 response to stimulus - stress - radiation
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Figure Legends 
Figure 1. Pedigrees of FTLD families. Black symbols indicate subjects affected by FTLD, red 
symbols subjects affected by cancer and blue symbols subjects affected by both diseases. Gray 
symbols represent the spouse parents or grandparents (who do not belong to the family carrying 
FTLD); note that both grandparents were considered spouses in families 3, 6, 11 and 14, because 
information about which grandparent carried FTLD was not available. Diagonal lines indicate the 
deceased, arrows the probands. Smaller symbols represent subjects deceased within few days from 
birth, stillborn or aborted. Asterisks indicate subjects whose MAPT genotype was determined as 
wild-type (not included in the statistical analysis). 
 
Figure 2. Tau protein interactome. a Tau (MAPT), in red, is used as seed to download direct 
protein interactors (first layer tau’s interactome); direct interactors of tau are used to download 
direct protein interactors of the first layer nodes generating the second layer tau’s interactome. b 
Updated version of A where all the first and second layer interactors (989 nodes) of tau associated 
with GO-BPs related to DNA damage, cell cycle checkpoints and chromatin/telomere maintenance 
are highlighted in dark blue. 
 
Figure 3. Tau mutations increase the risk of cancer. a Mutated tau alters microtubule dynamics 
producing an unstable mitotic spindle, which in turn leads to chromosome missegregation. b 
Mutated tau fails to protect chromatin structure and DNA integrity, producing chromosome 
structural aberrations. c Mutated tau induces an aberrant cell cycle activation. All these pathological 
events can increase the risk of developing cancer. 
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